# Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

> **NCT00556413** · PHASE2 · COMPLETED · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 42 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** fluorouracil
- **DRUG:** irinotecan hydrochloride
- **DRUG:** leucovorin calcium
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00556413
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2011-05
- **Final completion:** 2011-11-17
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00556413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00556413, "Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00556413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*